Livforsakringsbolaget Skandia Omsesidigt Sells 265,550 Shares of Pfizer Inc. (NYSE:PFE)

Livforsakringsbolaget Skandia Omsesidigt lowered its position in Pfizer Inc. (NYSE:PFE) by 85.4% in the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 45,223 shares of the biopharmaceutical company’s stock after selling 265,550 shares during the period. Livforsakringsbolaget Skandia Omsesidigt’s holdings in Pfizer were worth $1,200,000 as of its most recent SEC filing.

A number of other hedge funds have also recently modified their holdings of PFE. Sumitomo Mitsui DS Asset Management Company Ltd grew its stake in shares of Pfizer by 7.5% in the fourth quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 756,400 shares of the biopharmaceutical company’s stock worth $20,067,000 after acquiring an additional 52,578 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. grew its position in Pfizer by 7.3% in the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 14,075,637 shares of the biopharmaceutical company’s stock worth $373,427,000 after purchasing an additional 956,873 shares during the period. Migdal Insurance & Financial Holdings Ltd. lifted its holdings in shares of Pfizer by 19,570.5% during the 4th quarter. Migdal Insurance & Financial Holdings Ltd. now owns 800,000 shares of the biopharmaceutical company’s stock valued at $21,224,000 after buying an additional 795,933 shares during the period. Strategic Financial Concepts LLC purchased a new position in shares of Pfizer in the 4th quarter worth $2,281,000. Finally, Leo Wealth LLC grew its holdings in shares of Pfizer by 48.8% in the fourth quarter. Leo Wealth LLC now owns 35,767 shares of the biopharmaceutical company’s stock worth $949,000 after acquiring an additional 11,722 shares during the period. Institutional investors own 68.36% of the company’s stock.

Pfizer Stock Performance

Shares of NYSE PFE opened at $25.83 on Friday. The company has a market cap of $146.35 billion, a P/E ratio of 34.90, a P/E/G ratio of 0.66 and a beta of 0.64. Pfizer Inc. has a 52-week low of $24.48 and a 52-week high of $31.54. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The firm’s fifty day moving average is $26.29 and its two-hundred day moving average is $27.78.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, topping analysts’ consensus estimates of $0.48 by $0.15. The company had revenue of $17.76 billion for the quarter, compared to the consensus estimate of $17.26 billion. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The firm’s revenue for the quarter was up 24.7% on a year-over-year basis. During the same period in the previous year, the business earned $0.10 earnings per share. As a group, analysts anticipate that Pfizer Inc. will post 2.96 EPS for the current fiscal year.

Pfizer Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, January 24th will be issued a $0.43 dividend. The ex-dividend date of this dividend is Friday, January 24th. This is a positive change from Pfizer’s previous quarterly dividend of $0.42. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.66%. Pfizer’s dividend payout ratio (DPR) is 232.44%.

Wall Street Analyst Weigh In

PFE has been the subject of several research reports. Sanford C. Bernstein assumed coverage on shares of Pfizer in a research note on Thursday, October 17th. They issued a “market perform” rating and a $32.00 price objective on the stock. Wolfe Research initiated coverage on shares of Pfizer in a research note on Friday, November 15th. They set an “underperform” rating and a $25.00 price target on the stock. StockNews.com cut Pfizer from a “strong-buy” rating to a “buy” rating in a report on Wednesday, November 20th. UBS Group reduced their price target on Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a research report on Wednesday, January 8th. Finally, Guggenheim lowered their price objective on Pfizer from $35.00 to $33.00 and set a “buy” rating on the stock in a research report on Wednesday, December 11th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $31.92.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.